Trial Profile

Phase 2 dose-finding study of VERU-100 advanced hormone-sensitive prostate cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VERU 100 (Primary)
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

03 Jan 2022 Status changed from planning to recruiting, according to a Veru Healthcare media release.
09 Dec 2020 According to a Veru Inc media release, dosing in this study is anticipated to begin in the first quarter of calendar year 2021.
29 Jun 2020 According to a Veru Inc media release, this study is anticipated to begin in the fourth quarter of calendar year 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com